Research progress on preclinical efficacy evaluation of COVID-19 complicated with cytokine storm
10.3969/j.issn.1001-1978.2021.07.006
- Author:
Hui-Qin DING
1
;
Huan QIN
1
;
Xue-Hong CHEN
1
;
Yan-Tao HAN
1
;
Hui-Qin DING
2
;
Jian-Gang WANG
2
;
Fei LIU
3
Author Information
1. Basic Medical College, Qingdao University
2. Kanglitai Pharmaceutical Co., Ltd.
3. Shandong Academy of Pharmaceutical Sciences
- Publication Type:Journal Article
- Keywords:
animal model;
COVID-19;
cytokine storm;
pharmacodynamic evaluation;
recent advance;
SARS-CoV-2
- From:
Chinese Pharmacological Bulletin
2021;37(7):911-916
- CountryChina
- Language:Chinese
-
Abstract:
Studies have shown that COVID-19 patients infected with SARS-CoV-2 have severe pulmonary inflammation and cytokine storm, so the treatment of cytokine storm is an important part of rescuing critically ill patients with COVID-19. As an important cause of death, the preclinical study of cytokine storm is essential, and related experiments in vivo and in vitro are also the only way to develop new drugs for COVID-19 in the future. This paper reviews the in vitro and in vivo experimental methods of cytokine storm research articles at home and abroad in recent years, including the establishment of animal models, cell evaluation methods, pharmacodynamic evaluation indicators, etc., in order to provide reference and guidance for the experimental design methods of cytokine storm.
